IP Verse

Dosage Regimen For A S1P Receptor Agonist - EP3453387

The patent EP3453387 was granted to Novartis on Jun 3, 2020. The application was originally filed on Dec 21, 2009 under application number EP18201062A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3453387

NOVARTIS
Application Number
EP18201062A
Filing Date
Dec 21, 2009
Status
Granted And Under Opposition
May 1, 2020
Grant Date
Jun 3, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPMar 3, 2021HAMM & WITTKOPPWITHDRAWN
LABORATORIOS LICONSAMar 3, 2021DR SCHONWITHDRAWN
VON SEEBACHMar 3, 2021HAMM & WITTKOPPWITHDRAWN

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0627406
DESCRIPTIONWO0218395
DESCRIPTIONWO03097028
OPPOSITIONWO2009115954
OPPOSITIONWO2010072703
OPPOSITIONWO2010075239
SEARCHWO2009115954
SEARCHWO2009155475

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- KAPPOS L; ANTEL J; COMI G; MONTALBAN X; O'CONNOR P; POLMAN CH; HAAS T; KORN AA; KARLSSON G; RADUE EW, "Oral fingolimod (FTY720) for relapsing multiple sclerosis", N Engl J Med, (20060914), vol. 355, no. 11, pages 1124 - 40-
DESCRIPTION- ROBERT SCHMOUDER; DENISE SERRA; YIBIN WANG; JOHN M. KOVARIK; JOHN DIMARCO; THOMAS L. HUNT; MARIE-CLAUDE BASTIEN, "FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects", J. Clin. Pharmacol., (20060000), vol. 46, doi:doi:10.1177/0091270006289853, page 895, XP008107801
DESCRIPTION- MEHLING M; BRINKMANN V; ANTEL J; BAR-OR A; GOEBELS N; VEDRINE C; KRISTOFIC C; KUHLE J; LINDBERG RL; KAPPOS L, "FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis", Neurology, (20081014), vol. 71, no. 16, doi:doi:10.1212/01.wnl.0000327609.57688.ea, pages 1261 - 7, XP009165260
OPPOSITION- Anonymous, "Treatment guidelines for preventive treatment of migraine", Acta Neurol Taiwan, (20080601), vol. 17, no. 2, pages 132 - 148, XP055976695-
OPPOSITION- S. KROSSER et al., "Effect of Ceralifimod (ONO-4641) on Lymphocytes and Cardiac Function: Randomized, Double-Blind, Placebo-Controlled Trial With an Open-Label Fingolimod Arm", J. of Clin. Pharmacol., (20150000), vol. 55, no. 9, pages 1051 - 1060, XP055976691
OPPOSITION- V. BRINKMANN, "Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology", Pharmacology & Therapeutics, (20070000), vol. 115, doi:10.1016/j.pharmthera.2007.04.006, pages 84 - 105, XP022134156
OPPOSITION- Lublin Fred; Miller David H; Freedman Mark S; Cree Bruce A C; Wolinsky Jerry S; Weiner Howard; Lubetzki Catherine; Hartung Hans-Peter; Montalban Xavier; Uitdehaag Bernard M J; Merschhemke Martin; Li Bingbing; Putzki Norman; Liu Fonda C; Häring Dieter A; Kappos Ludwig, "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160128), vol. 387, no. 10023, doi:10.1016/S0140-6736(15)01314-8, ISSN 0140-6736, pages 1075 - 1084, XP029442340
OPPOSITION- Hobson Douglas E., Pourcher Emmanuelle, Martin W.R. Wayne, "Ropinirole and Pramipexole, the New Agonists", CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, WINNIPEG, CA, CA , (19990801), vol. 26, no. S2, doi:10.1017/S0317167100000068, ISSN 0317-1671, pages S27 - S33, XP055923472
OPPOSITION- J.A. DESMEULES, "The tramadol option", Eur. J. Pain, (20000000), vol. 4, doi:10.1053/eujp.1999.0163, XP008068602
OPPOSITION- L. KAPPOS et al., "Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis", N. ENGL. J. MED., (20060000), vol. 355, doi:10.1056/NEJMoa052643, pages 1124 - 1140, XP009072986
OPPOSITION- H. TEDESCO-SILVA et al., "FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation", Transplantation, (20050000), vol. 79, no. 11, pages 1553 - 1560, XP055976680
OPPOSITION- Tomohiko Harada; Darren Wilbraham; Guillemette La Borderie; Shinsuke Inoue; Jim Bush; A. John Camm, "Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects", British journal of clinical pharmacology, BLACKWELL SCIENTIFIC PUBL., GB, GB , (20170119), vol. 83, no. 5, doi:10.1111/bcp.13203, ISSN 0306-5251, pages 1011 - 1027, XP071602953
OPPOSITION- B. POIRIER et al., "A G protein-biased SIP i agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers", Sci. Signal., (20200000), vol. 13, pages 1 - 13, XP055976677
OPPOSITION- B.A. BROWN et al., "Fingolimod: A Novel Immunosuppressant for Multiple Sclerosis", The Annals of Pharmacotherapy, (20070000), vol. 41, doi:10.1345/aph.1G424, pages 1660 - 1668, XP009121784
SEARCH- BUDDE K ET AL, "First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, (20020101), vol. 13, no. 4, ISSN 1046-6673, pages 1073 - 1083, XP003016978 [Y] 1-10 * abstract * * page 1075, column r, paragraph 3 *-
SEARCH- David Kinshuck At Heartofengland Nhs Uk, "Blood pressure and diabetes", (20061204), URL: http://medweb.bham.ac.uk/easdec/prevention/Diabetes%20and%20Blood%20Pressure.htm, (20131105), XP055086741 [Y] 1-10 * the whole document *-
SEARCH- Oral fingolimod (FTY720), 0.5 or 1.25 mg, for 14 days has no effect on cardiac function, "World Congresson Treatment and Research on Multiple Sclerosis", Oral fingolimod (FTY720), 0.5 or 1.25 mg, for 14 days has no effect on cardiac function, SCHMOULDER R., ET AL., Multiple Sclerosis, London, Sage, (20080917), vol. 14, page S177, Abst P507, XP009127649 [Y] 1-10 * the whole document *-
SEARCH- KOYRAKH LEV ET AL, The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I., AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS MAR 2005, VOL. 5, NR. 3, PAGE(S) 529 - 536, (200503), ISSN 1600-6135, XP002562406 [Y] 1-10 * abstract * * page 534, column r, paragraphs 1-2; figure 5 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents